Emulated Effects of Glucagon-Like Peptide 1 Receptor Agonist Therapy in the General Population - PubMed
2 days ago
- #primary prevention
- #cardiovascular risk
- #GLP-1RA
- GLP-1 receptor agonists (GLP-1RAs) reduce cardiovascular risk in obese individuals with established CVD.
- Study emulates GLP-1RA use for primary prevention by applying risk factor changes from the SELECT trial.
- Model estimates 10-year CVD incidence and death using key risk factors like BMI, blood pressure, and cholesterol.
- Emulated GLP-1RA therapy reduced projected CVD incidence by 2.99% (22% relative reduction).
- Greater absolute risk reduction in men (3.14%) vs. women (2.7%), but similar relative reductions (21% vs. 23%).
- Risk reductions were smaller in nonobese individuals and those with lower baseline SCORE2 risk.
- Supports GLP-1RA therapy as a complement to primary prevention in high-risk individuals.
- Study funded by Novo Nordisk, but the company had no role in study design or analysis.